AbbVie Inc. ABBV
264.34
(0.78)
(0.29%)
as of 25 Sep
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
AbbVie Inc. (ABBV) Return on equity
AbbVie Inc.'s return on equity over the twelve months to 30 June 2026 was −208.1%, down 6364.0 percentage points from fiscal 2025 (6,155.9%). Over the past ten years it has ranged from −339.6% (fiscal 2018) to 6,155.9% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers General industry median of 6.97% and below the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 6,155.9% | 6,094.29 |
| FY2024 | 61.6% | 26.77 |
| FY2023 | 34.8% | (37.19) |
| FY2022 | 72.0% | (8.89) |
| FY2021 | 80.9% | (106.55) |
| FY2020 | 187.5% | 282.31 |
| FY2019 | −94.9% | 244.76 |
| FY2018 | −339.6% | (448.71) |
| FY2017 | 109.1% | (29.66) |
| FY2016 | 138.8% | (42.15) |
Against its own ten years
Low −339.6%
High 6,155.9%
Ten-year median
80.9%
Current reading's percentile
100
Return on equity against peers
| Company | Return on equity |
|---|---|
| LLY Eli Lilly and Company compare | 102.3% |
| AMGN Amgen Inc. compare | 91.5% |
| NVS Novartis AG compare | 30.4% |
| JNJ Johnson & Johnson compare | 25.7% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. compare | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. | −208.1% |
| Drug Manufacturers General industry median | 6.97% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement